AU2003208714A1 - Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity - Google Patents

Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity Download PDF

Info

Publication number
AU2003208714A1
AU2003208714A1 AU2003208714A AU2003208714A AU2003208714A1 AU 2003208714 A1 AU2003208714 A1 AU 2003208714A1 AU 2003208714 A AU2003208714 A AU 2003208714A AU 2003208714 A AU2003208714 A AU 2003208714A AU 2003208714 A1 AU2003208714 A1 AU 2003208714A1
Authority
AU
Australia
Prior art keywords
disorders
composition
dopamine
treatment
serotonin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003208714A
Other languages
English (en)
Inventor
Juliana B. Bronzova
Roelof W. Feenstra
Jeffrey C. Glennon
Andrew C. Mccreary
Eric Ronken
Jan Van Randen
Gustaaf J.M. Van Scharrenburg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals BV filed Critical Solvay Pharmaceuticals BV
Publication of AU2003208714A1 publication Critical patent/AU2003208714A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2003208714A 2002-02-14 2003-02-11 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity Abandoned AU2003208714A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020076344 EP1336406A1 (en) 2002-02-14 2002-02-14 Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
EP02076344.7 2002-02-14
PCT/EP2003/050015 WO2003068207A2 (en) 2002-02-14 2003-02-11 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity

Publications (1)

Publication Number Publication Date
AU2003208714A1 true AU2003208714A1 (en) 2003-09-04

Family

ID=27619173

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003208714A Abandoned AU2003208714A1 (en) 2002-02-14 2003-02-11 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity

Country Status (16)

Country Link
US (1) US20050038015A1 (cg-RX-API-DMAC7.html)
EP (2) EP1336406A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005517036A (cg-RX-API-DMAC7.html)
KR (1) KR20040081779A (cg-RX-API-DMAC7.html)
CN (1) CN1592614A (cg-RX-API-DMAC7.html)
AU (1) AU2003208714A1 (cg-RX-API-DMAC7.html)
BR (1) BR0306147A (cg-RX-API-DMAC7.html)
CA (1) CA2462688A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20040276A2 (cg-RX-API-DMAC7.html)
IL (1) IL160942A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA04004745A (cg-RX-API-DMAC7.html)
NO (1) NO20043833L (cg-RX-API-DMAC7.html)
PL (1) PL370632A1 (cg-RX-API-DMAC7.html)
RU (1) RU2004112546A (cg-RX-API-DMAC7.html)
WO (1) WO2003068207A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200404740B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517900A (en) 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AR032712A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
WO2007019880A1 (en) * 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
WO2007065713A2 (en) * 2005-12-08 2007-06-14 Axxonis Pharma Gmbh Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
EP2457571A1 (en) 2007-02-01 2012-05-30 Alan I. Green Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
NZ583193A (en) * 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
TW200936130A (en) * 2008-02-26 2009-09-01 Lundbeck & Co As H Uses of indane compounds
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
KR20130103662A (ko) * 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
CN111134894B (zh) * 2020-01-17 2022-02-22 上海长海医院 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
NZ517900A (en) * 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors

Also Published As

Publication number Publication date
NO20043833L (no) 2004-09-13
CN1592614A (zh) 2005-03-09
EP1476148A2 (en) 2004-11-17
WO2003068207A2 (en) 2003-08-21
EP1336406A1 (en) 2003-08-20
RU2004112546A (ru) 2005-03-27
ZA200404740B (en) 2005-08-23
JP2005517036A (ja) 2005-06-09
CA2462688A1 (en) 2003-08-21
KR20040081779A (ko) 2004-09-22
IL160942A0 (en) 2004-08-31
PL370632A1 (en) 2005-05-30
US20050038015A1 (en) 2005-02-17
HRP20040276A2 (en) 2005-04-30
MXPA04004745A (es) 2004-08-02
BR0306147A (pt) 2004-10-19
WO2003068207A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
EP1336406A1 (en) Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
Nichols Chemistry and structure-activity relationships of psychedelics
Bosker et al. Effects of single and repeated oral administration of fluvoxamine on extracellular serotonin in the median raphe nucleus and dorsal hippocampus of the rat
KR100832026B1 (ko) 세로토닌 재흡수 저해제와 5-ht2c 길항제, 역성 효현제또는 부분 효현제의 조합
Vos et al. Identification of 2-{2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl}-4, 5-dihydro-1 H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model
CA2502021A1 (en) Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
WO2013063269A2 (en) Compounds and methods of treating ocular disorders
CA2502032A1 (en) Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
Filippi et al. Endothelium-dependency of yohimbine-induced corpus cavernosum relaxation
Matsumoto et al. Functional regulation by dopamine receptors of serotonin release from the rat hippocampus: in vivo microdialysis study
Harsing Jr Dopamine and the Dopaminergic Systems of the Brain
WO2010010000A2 (en) Screening method, diagnostic method and small nucleic acid for the treatment of cns disorders
Kidd et al. New methoxy-chroman derivatives, 4 [N-(5-methoxy-chroman-3-yl) N-propylamino] butyl-8-azaspiro-(4, 5)-decane-7, 9-dione [(+/-)-S 20244] and its enantiomers,(+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors.
Ross et al. Robalzotan (NAD-299), a Novel Selective 5-HT~ 1~ A Receptor Antagonist
Monti et al. Sleep and waking in 5, 7-DHT-lesioned or (−)-pindolol-pretreated rats after administration of buspirone, ipsapirone, or gepirone
WATANABE et al. Dopamine receptor stimulating effects of chanoclavine analogues, tricyclic ergot alkaloids, in the brain
US20070142399A1 (en) Dual function drugs and uses thereof
HK1070277A (en) Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
TW568786B (en) A combination, pharmaceutical formulation, and kit for use in the treatment of affective disorders
Chagraoui et al. Ibogalogs induce antiseizure activity in rodents by a mechanism involving 5-HT2A/2C receptor activation with a major role of 5-HT2A receptors in the hippocampal CA3 subfield
Fuller et al. Fluoxetine at anorectic doses does not have properties of a dopamine uptake inhibitor
Hjorth et al. Cis-(+)-8-OH-1-CH3-DPAT,(+) ALK-3, a novel stereoselective pharmacological probe for characterizing 5-HT release-controlling 5-HT1A autoreceptors: an in vivo brain microdialysis study
Caicoya et al. Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist
Nathalie et al. INSERM U388
O'Sullivan et al. Inhibition of amine oxidases by the histamine-1 receptor antagonist hydroxyzine

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted